Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.
Commentary|Articles|November 2, 2026
AAO 2026 recap: Christopher J. Rapuano, MD, on the meeting's themes
Author(s)Kassi Filkins, Christopher J. Rapuano, MD
Christopher J. Rapuano, MD, discusses emergency eye care access, retina advances and responsible AI use in ophthalmology.
Advertisement
Advertisement
Timely access to care for sight-threatening eye injuries, therapies aimed at preserving and restoring vision in retinal disease, and the safe adoption of artificial intelligence (AI) in imaging and clinical workflows were among the threads running through the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, held October 9-12 in New Orleans, Louisiana. The program included an American Society of Ophthalmic Trauma session on managing ophthalmic trauma and a symposium on AI validation, transparency, and risk cosponsored by the Academy's Committee on Artificial Intelligence.
Related to this article
The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.
IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.
Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.
Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.
Andrew G. Lee, MD, and Drew Carey, MD, break down the link between optic neuritis and uveitis in central nervous system demyelinating disease.
Anat Galor, MD, MSPH, discusses subtyping dry eye, emerging diagnostic tools, and when to consider oral neuromodulation.
An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual eye exams as AI screening and new therapies reshape care.
Advertisement
Advertisement